+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antimalarial Drugs Market - Global Forecast 2026-2032- Product Image
Antimalarial Drugs Market - Global Forecast 2026-2032- Product Image
New

Antimalarial Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5967662
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antimalarial drugs market is adapting rapidly as senior leaders face supply disruptions, new therapy options, and evolving regulatory frameworks. Clinical innovation and changing procurement strategies are influencing the commercial landscape, driving organizations to reassess how they approach access, resilience, and stakeholder alignment across the pharmaceutical and healthcare sectors.

Market Snapshot: Antimalarial Drugs Market Growth and Outlook

The antimalarial drugs market expanded from USD 1.87 billion in 2025 to USD 1.99 billion in 2026 and is on track to reach USD 2.84 billion by 2032, with a projected CAGR of 6.12%. Market growth is driven by progress in pharmacotherapy, strengthened investment in drug procurement, and prioritization of flexible access solutions across both traditional endemic regions and emerging risk areas. These trends reflect an evolving landscape where innovation and adaptability are explicit requirements for commercial success.

Scope & Segmentation

This analysis delivers a comprehensive view of the antimalarial drugs market by addressing critical variables affecting operational and strategic planning for decision-makers:

  • Drug Classes: Market coverage extends to artemisinin-based combination therapies such as artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, and dihydroartemisinin-piperaquine, as well as non-artemisinin agents like chloroquine, mefloquine, primaquine, and quinine. Each class is evaluated based on usage patterns, resistance risk, and role in treatment protocols.
  • Administration Routes: The report details oral, injectable, and pediatric-specific formulations, clarifying their use in various care settings and their impact on clinical workflows.
  • Formulation Types: Segments include tablets, suspensions, dispersible formats, and injectables, providing insight into usability considerations for diverse patient segments.
  • Distribution Channels: Focuses on hospital pharmacies, retail pharmacies, and online platforms, examining regulatory oversight and the implications for access and supply stability.
  • End-User Segments: Assesses ambulatory care centers, clinics, and hospitals, highlighting their influence on demand generation and stewardship strategies.
  • Regions Assessed: Coverage includes the Americas; Europe, Middle East & Africa (EMEA); and Asia-Pacific, with nuanced analysis of regional differences in epidemiological risk, procurement frameworks, and supply chain maturity.
  • Technological Drivers: Examines diagnostic integration, digital traceability technologies, supply chain digitization, and pharmacovigilance platforms, all of which are shaping real-time oversight and enabling targeted deployment of therapies. Digital tools support monitoring, traceability, and informed interventions relevant to evolving clinical pathways.

Key Takeaways for Decision-Makers

  • Combination therapies are central to current malaria therapy strategies, prompting ongoing portfolio adjustments as resistance patterns develop and new agents are introduced for improved clinical outcomes.
  • Recent advances in formulation, particularly in dispersible tablets and suspensions, are expanding therapeutic options for pediatric and pregnant populations and supporting better adherence.
  • Progress in diagnostic technologies and targeted therapies are optimizing prescription practices, limiting unnecessary drug exposure, and fostering sustainable resistance management.
  • Multi-channel distribution strategies—including hospitals, retail, and online pharmacies—require cohesive pharmacovigilance measures and comprehensive traceability to safeguard quality and integrity across the antimalarial drug supply chain.
  • Localization strategies in manufacturing and packaging are minimizing lead times and improving agility, while cross-regional partnerships enhance supply chain resilience and help organizations better withstand market shocks.
  • Strategic contracting, such as collaborative procurement and risk-sharing agreements, is now integral to managing volatility from dynamic regulatory and policy environments.

Tariff Impact on Supply Chain and Procurement Dynamics

Recent tariff changes, particularly in the United States, have added complexity to the sourcing and localization of antimalarial drug supply chains. These adjustments prompt organizations to evaluate sourcing geographies, scrutinize supplier selection through enhanced risk analysis, and adapt contractual terms to address fluctuating costs and market exposure. Manufacturers are diversifying production footprints, and procurement teams are increasingly incorporating tariff sensitivity into contingency and inventory planning to strengthen resilience against unforeseen disruptions.

Methodology & Data Sources

This market report uses a robust, multidisciplinary methodology, synthesizing clinical literature, regulatory data, and operational audits. Targeted stakeholder interviews, including input from supply managers and clinicians, ensure insights are grounded in practical realities and inform evidence-based decision-making for antimalarial drug delivery and commercialization.

Why This Report Matters

  • Enables senior executives to refine commercial strategies by clarifying the impact of emerging therapy classes, distribution channels, and channel-specific risks on portfolio performance.
  • Provides operational leaders with benchmarking tools to compare regional procurement and supply chain models, supporting informed decisions for sustainable market expansion.
  • Facilitates alignment between clinical, manufacturing, and distribution teams by translating multidimensional evidence into focused priorities.

Conclusion

The antimalarial drugs market is characterized by ongoing clinical development and adaptive supply models. Strategic collaboration across manufacturing, distribution, and stewardship will shape future therapeutic access and ensure continued public health progress.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Antimalarial Drugs Market, by Drug Class
8.1. Artemisinin Based Combination Therapy
8.1.1. Artemether Lumefantrine
8.1.2. Artesunate Amodiaquine
8.1.3. Artesunate Mefloquine
8.1.4. Dihydroartemisinin Piperaquine
8.2. Non Artemisinin Therapies
8.2.1. Chloroquine
8.2.2. Mefloquine
8.2.3. Primaquine
8.2.4. Quinine
9. Antimalarial Drugs Market, by Route Of Administration
9.1. Injectable
9.2. Oral
10. Antimalarial Drugs Market, by Formulation
10.1. Injectables
10.2. Suspensions
10.3. Tablets
11. Antimalarial Drugs Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies
12. Antimalarial Drugs Market, by End User
12.1. Ambulatory Care Centers
12.2. Clinics
12.3. Hospitals
13. Antimalarial Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Antimalarial Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Antimalarial Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Antimalarial Drugs Market
17. China Antimalarial Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Laboratories
18.6. Alkem Laboratories
18.7. Alliance Pharma
18.8. Alvizia Health Care
18.9. Bayer AG
18.10. Cipla Inc.
18.11. Dr. Reddy's Laboratories
18.12. F. Hoffmann-La Roche Ltd.
18.13. GlaxoSmithKline plc
18.14. Glenmark Pharmaceuticals
18.15. Hikma Pharmaceuticals PLC
18.16. Ipca Laboratories Ltd.
18.17. Lincoln Pharmaceuticals
18.18. Lupin Limited
18.19. Merck KGaA
18.20. Mylan
18.21. Novartis AG
18.22. Pfizer Inc.
18.23. Sanofi Group
18.24. Strides Pharma Science Limited
18.25. Sun Pharmaceutical Industries Ltd.
18.26. Takeda Pharmaceutical Company
18.27. Teva Pharmaceuticals Industries Ltd.
18.28. Zydus Group
18.29. Zydus Lifesciences Ltd.
List of Figures
FIGURE 1. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 107. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 108. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 109. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 110. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 111. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 123. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 124. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 125. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 127. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 140. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 141. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 142. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 144. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 148. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 149. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 150. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 152. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 164. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 165. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 166. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 167. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 168. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 172. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 173. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 174. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 176. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 178. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 179. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 180. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 181. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 182. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 183. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 184. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 185. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 188. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 189. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 190. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 191. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 193. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. CHINA ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 196. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 197. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 198. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2032 (USD MILLION)
TABLE 199. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 200. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 201. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 202. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Antimalarial Drugs market report include:
  • Abbott Laboratories
  • Alkem Laboratories
  • Alliance Pharma
  • Alvizia Health Care
  • Bayer AG
  • Cipla Inc.
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Ipca Laboratories Ltd.
  • Lincoln Pharmaceuticals
  • Lupin Limited
  • Merck KGaA
  • Mylan
  • Novartis AG
  • Pfizer Inc.
  • Sanofi Group
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceuticals Industries Ltd.
  • Zydus Group
  • Zydus Lifesciences Ltd.

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.99 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.84 Billion
Compound Annual Growth Rate6.1%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Antimalarial Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Antimalarial Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Artesunate Medicine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Artesunate Medicine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Artemisinic Acid Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Artemisinic Acid Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 183 Pages
  • Global
From
Artemisinic Acid - Global Strategic Business Report - Product Image

Artemisinic Acid - Global Strategic Business Report

  • Report
  • 170 Pages
  • Global
From
Malaria Treatment Market - Global Strategic Business Report - Product Image

Malaria Treatment Market - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From

About the Antimalarial Market

The antimalarial market is a subset of the infectious diseases drugs market, which focuses on the treatment and prevention of malaria. Antimalarial drugs are used to treat and prevent the spread of the Plasmodium parasite, which is responsible for the disease. These drugs are typically administered orally, intravenously, or intramuscularly, depending on the severity of the infection. Common antimalarial drugs include chloroquine, artemisinin, and mefloquine. In addition to antimalarial drugs, the market also includes insecticides, insect repellents, and other preventive measures. These products are used to reduce the risk of infection by controlling the mosquito population, which is the primary vector for the Plasmodium parasite. Notable companies in the antimalarial market include GlaxoSmithKline, Sanofi, Novartis, and Merck. These companies produce a variety of antimalarial drugs, insecticides, and other preventive measures. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.